A topical product and an injected preparation ask different questions about exposure, formulation and safety. A favorable result from one route cannot establish that another route is more effective for skin texture or wrinkles. Avoiding the skin barrier does not, by itself, prove a clinical advantage.
Keep the route attached to the evidence
An often-cited experimental wound study involved rat wound chambers and measurements of connective-tissue accumulation. It was not a trial of injected GHK-Cu for cosmetic aging in people. The experimental setting is part of the evidence, not a detail that can be removed when retelling it.
FDA's current safety-risk page identifies limited human safety information for injectable GHK-Cu and concerns about aggregation and impurities. As checked October 1, 2026, it appears under withdrawn nominations; that is not an approval.
Delivery is not the same as benefit
An intervention can change exposure without producing a worthwhile outcome. To establish an advantage for injection, a study would need to measure the desired cosmetic result and compare it with an appropriate alternative, while collecting harms associated with that route.
The formulation also matters. A cosmetic ingredient specification cannot be assumed to establish the quality of an injectable preparation. A shared chemical name does not demonstrate equivalent testing, handling or suitability.
Why a clinician recommendation still needs context
A reported recommendation on a forum cannot be verified from the post alone. Even a real clinical discussion would be specific to a patient, product and intended purpose; it would not supply a general endorsement for readers with different circumstances.
The evidence question is therefore not simply which route delivers more material. It is whether a defined route and preparation produce benefits that justify their risks for the proposed use.
This article provides no injection instructions or alternative regimen. Topical research is worth evaluating on its own terms, but it does not fill the missing clinical evidence for an injected catalog product.